Klöß, StephanStephanKlößKretschmer, AnnaAnnaKretschmerStahl, LillyLillyStahlFricke, StephanStephanFrickeKoehl, UlrikeUlrikeKoehl2022-03-052022-03-052019https://publica.fraunhofer.de/handle/publica/25660310.1159/000495771Since the approval in 2017 and the outstanding success of Kymriah® and Yescarta®, the number of clinical trials investigating the safety and efficacy of chimeric antigen receptor-modified autologous T cells has been constantly rising. Currently, more than 200 clinical trials are listed on clinicaltrial.gov. In contrast to CAR-T cells, natural killer (NK) cells can be used from allogeneic donors as an ""off the shelf product"" and provide alternative candidates for cancer retargeting. This review summarises preclinical results of CAR-engineered NK cells using both primary human NK cells and the cell line NK-92, and provides an overview about the first clinical CAR-NK cell studies targeting haematological malignancies and solid tumours, respectively.enchimeric antigen receptornatural killer cellNK-92CAR-NK cellsolid tumourhaematological malignancies610620journal article